[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"paediatric-stroke\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:paediatric-stroke":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,54],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":30,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100635512","master-study-protocol-for-the-cohort-of-the-specialist-network-stroke-sn-strokestroke-core-100635512",false,"NCT07553650","Master Study Protocol for the Cohort of the Specialist Network Stroke (SN Stroke)(Stroke-CORE)","Master Study Protocol for the Cohort of the Specialist Network Stroke (SN Stroke) (Stroke-CORE)","Stroke-CORE","Inclusion Criteria:\n\n* Diagnosis of AIS or ICH; the AIS diagnosis may be diagnosed clinically or radiologically (i.e., focal neurological impairment of sudden onset, lasting more than 24 hours and of presumed vascular origin, or with proof of cerebral ischaemia corresponding to the clinical symptoms in neuroimaging); for ICH diagnosis requires clinical symptoms and radiological diagnosis of ICH\n* Hospital admission \\\u003C24h after symptom onset\n* Age 18+ years for the basic Modules AIS and ICH; age \\\u003C18 years for the basic Module paediatric stroke patients\n* Informed consent: Signed IC from patients capable of giving consent and understanding all content of the IC or IC of an appropriate patient representative or deferred consent, if patients are unable to consent themselves\n* Additional inclusion criteria are defined by the individual Modules\n\nExclusion Criteria:\n\n* In-hospital stroke\n* TIA\n* SAH\n* Stroke as a complication of a medical procedure\n* Enrolment in a randomised placebo-controlled interventional trial\n* Already enrolled in the SN STROKE base cohort","ALL",{"count":19,"type":20},12750,"ESTIMATED","90 Days","OBSERVATIONAL","The Stroke-CORE cohort aims to provide a comprehensive and up-to-date understanding of stroke care in Germany. To achieve this, patients are followed along the entire continuum of care-from initial management before hospital admission, through acute treatment, rehabilitation, and follow-up care, to the prevention of recurrent strokes. Strokes occurring in childhood are also included in this cohort study.\n\nIn addition, the study seeks to establish effective structures for the early identification and inclusion of patients in clinical research (screening). In this context, structured screening processes are being implemented across all levels of care at participating sites within the Network University Medicine (NUM), a collaboration of German university hospitals. At the same time, the cohort serves as a platform within this network to systematically address open research questions in various areas of stroke care and to support the targeted planning and conduct of future clinical studies.\n\nThe study includes patients with ischemic stroke (caused by a blocked blood vessel) or intracerebral hemorrhage (bleeding within the brain). Participation takes place in different thematic modules, each focusing on specific aspects of the disease course and its management. These modules address, among other topics, acute hospital treatment, measures to prevent recurrent strokes (secondary prevention), possible complications, pre-hospital care, rehabilitation, follow-up care, and long-term outcomes such as physical recovery, independence in daily life, and cognitive functions including memory and concentration.\n\nAs part of the study, a range of data is collected. This includes sociodemographic information (such as age and living situation) as well as medical data, for example on prior conditions, diagnoses, treatments, and comorbidities. In addition, patients' health status is assessed at multiple time points in order to better understand the course of the disease. Depending on the level of participation, data collection may be complemented by the collection of biological samples, such as blood. These are obtained either during routine clinical procedures or through simple, minimally burdensome (non-invasive) methods.\n\nThe study is structured into several levels that differ in the scope and depth of data collection. The basic level includes essential information, while higher levels involve more detailed assessments. In addition, some levels include the collection of biological samples, and there are optional supplementary modules in which patients may participate voluntarily. This tiered approach allows participation to be flexibly adapted to the individual situation while contributing to a nuanced and comprehensive understanding of stroke care.",[25,26,27,28,29],"Intracerebral Haemorrhage","Paediatric Stroke","Stroke Acute","Stroke","Ischemic Stroke",[28,31,32,26,33,34,35,36,37,38,39,40],"ischemic stroke","Intracerebral Hemorrhage","Cerebrovascular Disorders","Brain Diseases","Vascular Diseases","Cardiovascular Diseases","Brain Infarction","Embolic Stroke","Thrombotic Stroke","Acute","NOT_YET_RECRUITING","2026-04-23",{"date":44,"type":45},"2026-04-28","ACTUAL",{"date":47,"type":20},"2026-05-01",{"date":49,"type":20},"2030-06-30",{"name":51,"class":52},"Charite University, Berlin, Germany","OTHER",12,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":11,"sex":17,"minAge":62,"maxAge":63,"enrollmentInfo":64,"targetDuration":4,"studyType":66,"phases":67,"briefSummary":69,"conditions":70,"keywords":71,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":90},"100429554","phase-3-high-dose-steroids-in-children-with-stroke-100429554","NCT04873583","High Dose Steroids in Children With Stroke","High Dose Steroids in Children With Stroke and Unilateral Focal Arteriopathy: A Multicentre Randomized Controlled Trial PASTA (Paediatric Arteriopathy Steroid Aspirin) Trial","PASTA","Inclusion Criteria:\n\n1. Informed consent of the legal representative of the trial participant documented by signature\n2. Age \\> 6 months \\& \\\u003C 18 years at time of stroke\n3. Randomisation possible within 48 hours of diagnosis and maximum 96 hours after stroke onset\n4. Unilateral arteriopathy according to the following criteria:\n\n   * Newly acquired neurologic deficits\n   * Specific neuroimaging (MRA) features of either\n\n     * unilateral stenosis, or\n     * unilateral vessel irregularities within the Central Nervous System (CNS)\n5. Unless otherwise defined in the national addendum: Female participants age ≥ 13: Negative pregnancy test (blood or urine)\n\nExclusion Criteria:\n\n1. Previous stroke\n2. Known syndromal disorders, as e.g. Trisomy 21, Neurofibromatosis type 1\n3. Known genetic vasculopathies as e.g. posterior fossa anomalies, hemangioma, arterial anomalies, cardiac anomalies and eye anomalies syndrome (PHACES), actin alpha 2 (ACTA II)\n4. Moyamoya or sickle cell disease\n5. Small vessel cerebral vasculitis (primary CNS vasculitis)\n6. Bilateral arteriopathy\n7. Arterial dissection(s)\n8. Evidence of underlying systemic disorders, as e.g. lupus, rheumatoid problems\n9. Secondary CNS angiitis due to infections (meningitis, endocarditis, borreliosis), or generalised angiitis due to rheumatic or other autoimmune problems\n10. Progressive large to medium childhood primary angiitis of the CNS (cPACNS ) with 2 of the following 3 criteria:\n\n    1. pre-existing progressive neurocognitive dysfunction\n    2. bilateral MRI lesions\u002Fvessel involvement\n    3. small vessel arterial stenosis\n11. On steroid treatment at disease onset\n12. Contraindication to steroid treatment as e.g. a congenital or acquired immunodeficiency\n13. Inability to follow the procedures of the study, e.g. due to language problems\n14. Participation in another interventional study within the 30 days preceding the indication stroke and during the present study","6 Months","17 Years",{"count":65,"type":20},70,"INTERVENTIONAL",[68],"PHASE3","This clinical trial deals with focal cerebral arteriopathy and childhood stroke, a rare but devastating condition.\n\nFocal cerebral arteriopathy (FCA) is an inflammatory vessel wall disease provoked by infection and there is increasing evidence that inflammatory processes play a crucial role in childhood stroke, influencing the outcome of the disease.\n\nAnalysis of existing data suggests that outcomes are improved and that there is less stroke recurrence in children treated with steroids to reduce the acute inflammatory processes. This clinical trial will be conducted in over 20 hospitals in several countries in order to investigate this.\n\nParticipants will be randomly separated into two groups. The first group will be treated with standard of care (including aspirin) combined with high dose steroids. The second group will be treated with standard of care (including aspirin) but without steroid treatment.\n\nThe objective is to investigate if children treated with a combination of high dose steroid and aspirin will have a better and quicker recovery of FCA, better clinical functional outcome, and less recurrence compared to children treated with aspirin alone.\n\nThis project has been identified by international pediatric stroke experts as the most important topic for a clinical trial in the field and is as well one of the most important research priorities identified by parents. The study results will also provide insight into the evolution of inflammatory vessel disease.",[26],[72,28,73,74,75,76,77,78,79],"Ischemic","Pediatric","Steroids","Unilateral","Focal","Arteriopathy","Neurology","Cerebral","RECRUITING","2025-11-17",{"date":83,"type":45},"2025-11-18",{"date":85,"type":45},"2021-11-16",{"date":87,"type":20},"2026-07",{"name":89,"class":52},"Insel Gruppe AG, University Hospital Bern",35]